Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Duramed Pharmaceuticals, a subsidiary of Barr Pharmaceuticals, has launched its marketing campaign for Enjuvia for the treatment of moderate-to-severe vaginal dryness and pain with intercourse: symptoms of vulvar and vaginal atrophy associated with menopause.
Subscribe to our email newsletter
Enjuvia is claimed to be the first and only plant-derived oral estrogen approved by FDA for the treatment of these specific symptoms associated with vaginal atrophy.
James Simon, clinical professor of obstetrics and gynecology at George Washington University, said: “Enjuvia has been shown in clinical studies to provide relief of moderate to severe vaginal dryness and pain with intercourse: symptoms of vulvar and vaginal atrophy associated with menopause. Enjuvia’s indication for the treatment of these moderate to severe vaginal symptoms associated with menopause affords women and healthcare professionals a new and effective treatment option for two of the most common symptoms associated with vaginal atrophy.”